Special Regulatory T Cell Review: The Resurgence of the Concept of Contrasuppression in Immunoregulation

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 2007 Dec 25

PMID 18154618

Citations 32

Authors

Thomas Lehner

Affiliations

Soon will be listed here.

Abstract

The original concept of contrasuppression (CS) is evident in many immunoregulatory mechanisms. Inhibition of suppressor activity--CS--may be critical in microbial infection and autoimmunity. The major cellular interactions involved in suppression are the CD25+ FoxP3+ CD4+ T regulatory cells, programmed death-1 (PD-1) : PD-L1/L2 and cytotoxic T lymphocyte antigen-4 (CTLA-4) : CD80/86 pathways. These cellular functions are affected by dendritic cells (DC) and a complex array of cytokines of which interleukin (IL)-2, IL-10, IL-6 and transforming growth factor-beta (TGF-beta) are especially significant. Inhibition of regulatory cells, suppressor pathways or cytokines, is consistent with CS and can be attributed to IL-6, IL-2, PD-1 or PD-L-1 antibodies, blockade of CTLA-4 : CD80/86 pathway, inhibition of CD40-CD40L pathways, and TGF-beta, IL-10 antibodies. Contrasuppression may regulate innate immunity by Toll-like receptor expressed not only in non-cognate DC, monocytes, natural killer cells and gammadelta T cells but also in adaptive T cells. Furthermore, cross-talk between innate and adaptive immunity may be facilitated by contrasuppressor activity. ''What's in a name? That which we call a rose by any other name would smell as sweet.'' From Romeo and Juliet (II, 47-8) W. Shakespeare.

Citing Articles

Enhanced synergistic antitumor effect of a DNA vaccine with anticancer cytokine, MDA-7/IL-24, and immune checkpoint blockade.

Miri S, Pourhossein B, Hosseini S, Keshavarz M, Shahmahmoodi S, Zolfaghari M Virol J. 2022; 19(1):106.

PMID: 35752792 PMC: 9233788. DOI: 10.1186/s12985-022-01842-x.

Corneal Dendritic Cell Dynamics Are Associated with Clinical Factors in Type 1 Diabetes.

Colorado L, Beecher L, Pritchard N, Al Rashah K, Dehghani C, Russell A J Clin Med. 2022; 11(9).

PMID: 35566743 PMC: 9101330. DOI: 10.3390/jcm11092611.

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors.

Shen P, Han L, Ba X, Qin K, Tu S Front Pharmacol. 2021; 12:678409.

PMID: 34290608 PMC: 8287409. DOI: 10.3389/fphar.2021.678409.

"Corneal Nerves, CD11c Dendritic Cells and Their Impact on Ocular Immune Privilege".

Niederkorn J Front Immunol. 2021; 12:701935.

PMID: 34220866 PMC: 8253307. DOI: 10.3389/fimmu.2021.701935.

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?.

Denis M, Duruisseaux M, Brevet M, Dumontet C Front Immunol. 2020; 11:492.

PMID: 32265935 PMC: 7098964. DOI: 10.3389/fimmu.2020.00492.

References

Yamazaki T, Akiba H, Koyanagi A, Azuma M, Yagita H, Okumura K . Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol. 2005; 175(3):1586-92. DOI: 10.4049/jimmunol.175.3.1586. View

Green D, Eardley D, Kimura A, Murphy D, Yamauchi K, GERSHON R . Immunoregulatory circuits which modulate responsiveness to suppressor cell signals: characterization of an effector cell in the contrasuppressor circuit. Eur J Immunol. 1981; 11(12):973-80. DOI: 10.1002/eji.1830111205. View

Liu H, Komai-Koma M, Xu D, Liew F . Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci U S A. 2006; 103(18):7048-53. PMC: 1444884. DOI: 10.1073/pnas.0601554103. View

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

Sutmuller R, Morgan M, Netea M, Grauer O, Adema G . Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol. 2006; 27(8):387-93. DOI: 10.1016/j.it.2006.06.005. View

Shevach E, Stephens G . The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity?. Nat Rev Immunol. 2006; 6(8):613-8. DOI: 10.1038/nri1867. View

Day C, Kaufmann D, Kiepiela P, Brown J, Moodley E, Reddy S . PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006; 443(7109):350-4. DOI: 10.1038/nature05115. View

Petrovas C, Casazza J, Brenchley J, Price D, Gostick E, Adams W . PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med. 2006; 203(10):2281-92. PMC: 2118095. DOI: 10.1084/jem.20061496. View

Freeman G, Wherry E, Ahmed R, Sharpe A . Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med. 2006; 203(10):2223-7. PMC: 2118103. DOI: 10.1084/jem.20061800. View

10.

Trautmann L, Janbazian L, Chomont N, Said E, Gimmig S, Bessette B . Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006; 12(10):1198-202. DOI: 10.1038/nm1482. View

11.

Griffith T, Kazama H, Vanoosten R, Earle Jr J, Herndon J, Green D . Apoptotic cells induce tolerance by generating helpless CD8+ T cells that produce TRAIL. J Immunol. 2007; 178(5):2679-87. DOI: 10.4049/jimmunol.178.5.2679. View

12.

Kitazawa Y, Fujino M, Wang Q, Kimura H, Azuma M, Kubo M . Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplantation. 2007; 83(6):774-82. DOI: 10.1097/01.tp.0000256293.90270.e8. View

13.

Zheng Y, Rudensky A . Foxp3 in control of the regulatory T cell lineage. Nat Immunol. 2007; 8(5):457-62. DOI: 10.1038/ni1455. View

14.

Chen W, Jin W, Hardegen N, Lei K, Li L, Marinos N . Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003; 198(12):1875-86. PMC: 2194145. DOI: 10.1084/jem.20030152. View

15.

Griffin M, Hong D, Holman P, Lee K, Whitters M, OHerrin S . Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol. 2000; 164(9):4433-42. DOI: 10.4049/jimmunol.164.9.4433. View

16.

Latchman Y, Wood C, Chernova T, Chaudhary D, Borde M, Chernova I . PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001; 2(3):261-8. DOI: 10.1038/85330. View

17.

Carter L, Fouser L, Jussif J, Fitz L, Deng B, Wood C . PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol. 2002; 32(3):634-43. DOI: 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9. View

18.

Lehner T, Lamb J, Kontiainen S . Cell-bound helper and suppressor factors in primate lymphocytes. Clin Exp Immunol. 1982; 47(3):706-14. PMC: 1536432. View

19.

Lehner T . The relationship between human helper and suppressor factors to a streptococcal protein antigen. J Immunol. 1982; 129(5):1936-40. View

20.

Smith H, Green D, Smathers P, GERSHON R, Raveche E, Steinberg A . Induction of autoimmunity in normal mice by thymectomy and administration of polyclonal B cell activators: association with contrasuppressor function. Clin Exp Immunol. 1983; 51(3):579-86. PMC: 1536771. View